MA27674A1 - Derives d'indole tricycliques et leur utilisation dans le cadre du traitement de la maladie d'alzheimer - Google Patents

Derives d'indole tricycliques et leur utilisation dans le cadre du traitement de la maladie d'alzheimer

Info

Publication number
MA27674A1
MA27674A1 MA28563A MA28563A MA27674A1 MA 27674 A1 MA27674 A1 MA 27674A1 MA 28563 A MA28563 A MA 28563A MA 28563 A MA28563 A MA 28563A MA 27674 A1 MA27674 A1 MA 27674A1
Authority
MA
Morocco
Prior art keywords
alzheimer
disease
treatment
indole derivatives
tricyclic indole
Prior art date
Application number
MA28563A
Other languages
English (en)
French (fr)
Inventor
Emmanuel Hubert Demont
Sally Redshaw
Daryl Simon Walter
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27674A1 publication Critical patent/MA27674A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA28563A 2003-04-23 2005-10-19 Derives d'indole tricycliques et leur utilisation dans le cadre du traitement de la maladie d'alzheimer MA27674A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0309221.0A GB0309221D0 (en) 2003-04-23 2003-04-23 Novel compounds

Publications (1)

Publication Number Publication Date
MA27674A1 true MA27674A1 (fr) 2005-12-01

Family

ID=9957152

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28563A MA27674A1 (fr) 2003-04-23 2005-10-19 Derives d'indole tricycliques et leur utilisation dans le cadre du traitement de la maladie d'alzheimer

Country Status (16)

Country Link
US (1) US20060229302A1 (enExample)
EP (1) EP1620438A1 (enExample)
JP (1) JP2006524206A (enExample)
KR (1) KR20050111797A (enExample)
CN (1) CN1809573A (enExample)
BR (1) BRPI0409622A (enExample)
CA (1) CA2523291A1 (enExample)
CO (1) CO5700829A2 (enExample)
GB (1) GB0309221D0 (enExample)
IS (1) IS8135A (enExample)
MA (1) MA27674A1 (enExample)
MX (1) MXPA05011365A (enExample)
NO (1) NO20055442L (enExample)
RU (1) RU2005136370A (enExample)
WO (1) WO2004094430A1 (enExample)
ZA (1) ZA200508041B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0316629A (pt) * 2002-11-27 2005-10-11 Elan Pharm Inc Uréias e carbamatos substituìdos
GB0328900D0 (en) * 2003-12-12 2004-01-14 Glaxo Group Ltd Novel compounds
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
GB0411404D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
JP2008513433A (ja) * 2004-09-21 2008-05-01 ファイザー・プロダクツ・インク 中枢神経系の症状の治療において有用なn−エチルヒドロキシエチルアミン
GB0422765D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422766D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422755D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
WO2006088705A1 (en) * 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
GB0506562D0 (en) * 2005-03-31 2005-05-04 Glaxo Group Ltd Novel compounds
AU2006235344B2 (en) 2005-04-08 2012-07-26 Comentis, Inc. Compounds which inhibit beta-secretase activity and methods of use thereof
WO2007019078A2 (en) * 2005-08-03 2007-02-15 Merck & Co., Inc. Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
EP1971598A1 (en) * 2005-11-21 2008-09-24 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
JP5440984B2 (ja) 2007-05-25 2014-03-12 アムジエン・インコーポレーテツド β−セクレターゼ修飾剤としての置換ヒドロキシエチルアミン化合物および使用方法
US8163909B2 (en) 2007-05-25 2012-04-24 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
FR2919286A1 (fr) 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
FR2919288B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique.
FR2919285B1 (fr) 2007-07-27 2012-08-31 Sanofi Aventis Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique.
MX2010001076A (es) * 2007-07-27 2010-03-09 Sanofi Aventis Derivados de 1,2,3,4-tetrahidropirrolo-[1,2-a]-pirazina-6-carboxam ida y 2,3,4,5-tetrahidropirrollo [1,2,a] [1,4]-diazepina-7-carboxa mida, preparacion y su uso terapeutico.
FR2919289B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique.
US9096541B2 (en) 2012-03-29 2015-08-04 Oklahoma Medical Research Foundation Inhibition of memapsin 1 cleavage in the treatment of diabetes
IL273428B2 (en) * 2017-09-22 2023-09-01 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
US12043631B2 (en) 2017-10-13 2024-07-23 Purdue Research Foundation BACE1 inhibitors for the treatment of Alzheimer's disease
WO2019075358A1 (en) * 2017-10-13 2019-04-18 Ghosh Arun K BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510474A (ja) * 1997-02-04 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア カテプシンdのナノモルの非ペプチド阻害剤
US6207664B1 (en) * 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
ES2252257T3 (es) * 2000-06-30 2006-05-16 Elan Pharmaceuticals, Inc. Compuestos para tratar la enfermedad de alzheimer.

Also Published As

Publication number Publication date
JP2006524206A (ja) 2006-10-26
MXPA05011365A (es) 2005-11-28
US20060229302A1 (en) 2006-10-12
GB0309221D0 (en) 2003-06-04
NO20055442L (no) 2005-11-17
ZA200508041B (en) 2007-02-28
CA2523291A1 (en) 2004-11-04
CN1809573A (zh) 2006-07-26
RU2005136370A (ru) 2006-05-27
CO5700829A2 (es) 2006-11-30
BRPI0409622A (pt) 2006-04-18
KR20050111797A (ko) 2005-11-28
WO2004094430A1 (en) 2004-11-04
IS8135A (is) 2005-11-21
EP1620438A1 (en) 2006-02-01
AU2004232475A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
MA27674A1 (fr) Derives d'indole tricycliques et leur utilisation dans le cadre du traitement de la maladie d'alzheimer
EP2011513A4 (en) THERAPEUTIC AGENTS AGAINST ALZHEIMER DISEASE AND CANCER
EP1689348A4 (en) OLIGOSACCHARIDE COMPOSITIONS AND ITS USE IN THE TREATMENT OF INFECTIONS
MA29084B1 (fr) Derives d'indenyle et leur utilisation dans le traitement de troubles neurologiques
EP1651195A4 (en) PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
EP1578253A4 (en) PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC DISEASE
EP1490050A4 (en) METHOD FOR TREATING ALZHEIMER AND COGNITIVE IMPROVEMENT
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
EP1604664A4 (en) MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND BLOOD HIGH PRESSURE
ATE374204T1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
DK1334091T3 (da) Thioflavinderivater og deres anvendelse til diagnose og terapi af Alzheimer's sygdom
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
EP1994152A4 (en) IN THE TREATMENT OF TUMORS AND OTHERS SUFFERING THE REMOVAL OR DESTROYING OF CELLS, EFFECTIVE PEPTIDES
NO20022680L (no) Farmasoytiske kombinasjoner og deres anvendelse ved behandling av gastrointestinale forstyrrelser
EP1007048A4 (en) IDENTIFICATION OF MEANS FOR TREATING ALZHEIMERISCHEN DISEASE
EP1656359A4 (en) MACROCYCLIC BETA-SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
MA28806B1 (fr) Derives d'arylsulfonylstilbene destines au traitement de l'insomnie et de conditions apparentees
NO20006113L (no) Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer
NO20024924D0 (no) Anvendelse av bradykardiale substanser ved behandling av myokardiale sykdommer i forbindelse med hypertrofi og nyemedikamentkombinasjoner
EP1474126A4 (en) TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER DISEASE
FR2835255B1 (fr) Test pour identifier des inhibiteurs de beta-secretases, procede de criblage de ces inhibiteurs, et nouveaux inhibiteurs de beta-secretases pour leur utilisation dans le traitement de la maladie d'alzheimer
EP1855679A4 (en) AMINOMETHYL-BETA-SEKRETASE-INHIBITOR FOR THE TREATMENT OF ALZHEIMER
EP1567556A4 (en) RECOMBINANT IMMUNOTOXIN AND USE IN THE TREATMENT OF TUMORS
EP1532258A4 (en) TREATMENT OF A VASCULAR MALFUNCTION AND MORBUS ALZHEIMER
NO20040659L (no) Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom